First disclosure of NX-2127, an oral targeted degrader of Bruton's tyrosine kinase (BTK) with concurrent immunomodulatory activity for the treatment of B-cell malignancies

Jeffrey Wu

Robert Cass

Ganesh Cherala

Cristiana Guiducci

Timothy Ingallinera

Dane Karr

Daisuke Kato

Aileen Kelly

Zef Allyn Konst

Joel McIntosh

Jenny McKinnell

Jeff Mihalic

Mark A. Noviski

Ge Peng

Luz Perez

Janine Powers

Daniel W. Robbins

Ryan Rountree

May Tan

Austin Tenn-McClellan

Jordan Ye

0 views
0 downloads

Powered byMorressier logo black

Discover more research and events on morressier.com